Medication-Assisted Treatment and Nursing Home Admission: What to Ask
The phrase "medication-assisted treatment" is still widely used, but federal agencies increasingly use medications for opioid use disorder (MOUD) to describe medications used to treat opioid use disorder.
SAMHSA identifies three medications used for OUD treatment: buprenorphine, methadone, and naltrexone.
For a person who needs skilled nursing or long-term care, the central question is not whether the facility is comfortable with the diagnosis.
It is:
How will the resident’s lawful prescribed treatment continue without interruption while the facility meets the resident’s nursing and rehabilitation needs?
Do not accept a blanket "we don’t take MAT" answer without clarification
The U.S. Department of Justice explains that people taking legally prescribed medication to treat OUD may be protected by the Americans with Disabilities Act when they are not engaged in the illegal use of drugs.
DOJ specifically gives an example of a skilled nursing facility refusing admission solely because an applicant takes prescribed MOUD and identifies that kind of blanket policy as an ADA concern.
HHS and DOJ have also entered compliance agreements involving skilled nursing facilities accused of denying admission to people using prescribed OUD medication.
A facility can still evaluate whether it can meet an applicant’s individual clinical needs. But the review should not stop at the medication name or diagnosis.
If a denial appears to be based solely on prescribed MOUD, families can ask for the reason in writing and consider contacting disability-rights or legal resources.
Identify the exact medication and treatment arrangement
Record:
Medication: buprenorphine / methadone / naltrexone / other prescribed treatment
Prescriber or program: ____________________
Current dose and schedule per order: ____________________
Pharmacy/dispensing source: ____________________
Next appointment: ____________________
Transportation needed: Yes / No
Do not stop MOUD during a care transition unless the treating clinician directs a change.
SAMHSA notes that these medicines can be used long term and advises consulting the treating clinician before discontinuation.
Methadone may require a different logistics plan
Methadone used to treat OUD is generally dispensed through a SAMHSA-certified opioid treatment program (OTP) under federal rules.
That can create practical questions for a nursing-home admission:
- Which OTP currently provides the medication?
- How will the resident receive treatment after the move?
- Is transportation required?
- Are take-home or other dispensing arrangements available under the resident’s current program and applicable rules?
- Who communicates with the OTP?
- What happens on weekends or holidays?
Do not assume the nursing-home pharmacy can simply replace the OTP arrangement.
Buprenorphine and naltrexone have different workflows
SAMHSA notes that buprenorphine can be prescribed in office-based and other care settings, while naltrexone is another FDA-approved medication for OUD.
Ask how the facility will coordinate the resident’s exact medication with:
- the current prescriber;
- the facility pharmacy;
- appointment scheduling;
- administration records;
- required follow-up; and
- any clinician-directed monitoring.
The workflow should be based on the actual prescription—not a generic "MAT policy."
Reconcile pain treatment separately
A resident receiving MOUD may also have acute or chronic pain, especially after surgery or hospitalization.
Do not assume OUD treatment means pain must be ignored or that the MOUD dose should be changed.
Ask the hospital, nursing-home clinician, pain team, and OUD prescriber to coordinate a plan before transfer when possible.
Families should not adjust MOUD or pain medication on their own.
Ask about controlled-medication storage and administration without stigma
The facility should explain how it handles prescribed controlled medications under its normal medication-management policies.
Questions include:
- Who receives and stores the medication?
- Who administers it?
- What happens if a scheduled dose is unavailable?
- Who contacts the prescriber or OTP?
- How is an outside appointment documented?
The answer should focus on safe medication management—not moral judgment about the diagnosis.
Include behavioral-health continuity
Medication is one part of OUD care.
Ask whether the resident has counseling, peer support, psychiatry, recovery services, or other supports that should continue after the move.
SAMHSA emphasizes patient-centered treatment and recovery supports. A nursing-home placement should not unnecessarily disconnect the resident from an established treatment network.
Admission checklist
- [ ] exact MOUD medication documented;
- [ ] prescriber or OTP identified;
- [ ] next dose protected during transfer;
- [ ] pharmacy/dispensing route confirmed;
- [ ] methadone OTP logistics confirmed if applicable;
- [ ] transportation arranged if needed;
- [ ] behavioral-health follow-up preserved;
- [ ] pain plan coordinated when relevant;
- [ ] after-hours medication problem contact identified; and
- [ ] any admission denial is based on individualized capability, not a blanket MOUD prohibition.
Frequently asked questions
Is taking prescribed buprenorphine or methadone the same as illegal drug use under the ADA?
DOJ states that legally prescribed medication used under supervision of a licensed health professional, including MOUD, is not treated as "illegal use of drugs" for this purpose when the person is not currently engaging in illegal drug use.
Must every nursing home accept every person who takes MOUD?
No. Facilities may assess whether they can meet the applicant’s individual medical and care needs. The concern is a blanket diagnosis- or medication-based exclusion rather than individualized review.
Can the nursing home stop MOUD during rehab?
Medication changes belong to the treating clinicians. Do not assume a temporary nursing-home stay is a reason to discontinue established OUD treatment.
The practical goal
A hospital-to-nursing-home transfer should protect treatment continuity so the resident does not lose an evidence-based medication simply because the care setting changed.
Primary sources checked
- U.S. Department of Justice — The ADA and Opioid Use Disorder
- SAMHSA — Medications for Opioid Use Disorder
- SAMHSA — Methadone
- HHS OCR — North End Rehabilitation & Healthcare Center Voluntary Resolution Agreement
Editorial/source review: October 16, 2026. General education only. OUD treatment, controlled-medication dispensing, methadone OTP arrangements, pain treatment, admission decisions, and disability-rights questions require individualized clinical, legal, and state/federal program review.
Next step for families: Browse senior-care communities to compare local options, or use the Care Finder to organize the care needs and your next questions. Always verify current services, staffing, clinical capability, costs, and availability directly with the provider.
